MedTrace Logo

Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer

NCT01801644 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2013-03-01

No results posted yet for this study

Summary

To evaluate the efficacy and safety of neoadjuvant gemcitabine and cisplatin (gem/cis) in locally advanced bladder cancer.

Conditions

Interventions

DRUG

gemcitabine plus cisplatin

gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion

Sponsors & Collaborators

  • Barmherzige Brüder Vienna

    lead OTHER

Principal Investigators

  • Johannes Meran, M.D. · Barmherzige Brüder Vienna

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2013-01-31
Completion
2013-02-28

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01801644 on ClinicalTrials.gov